American National Bank decreased its stake in shares of Medtronic PLC (NYSE:MDT) by 7.0% during the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 55,917 shares of the medical technology company’s stock after selling 4,181 shares during the period. Medtronic PLC comprises about 1.7% of American National Bank’s investment portfolio, making the stock its 20th largest position. American National Bank’s holdings in Medtronic PLC were worth $4,302,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Crow Point Partners boosted its stake in shares of Medtronic PLC by 26.7% in the third quarter. Crow Point Partners now owns 545 shares of the medical technology company’s stock valued at $36,000 after buying an additional 115 shares during the last quarter. J. Goldman & Company acquired a new stake in shares of Medtronic PLC during the third quarter valued at approximately $6,821,000. Capstone Asset Management Company boosted its stake in shares of Medtronic PLC by 37.1% in the fourth quarter. Capstone Asset Management Company now owns 346,388 shares of the medical technology company’s stock valued at $26,644,000 after buying an additional 93,753 shares during the last quarter. Vontobel Asset Management boosted its stake in shares of Medtronic PLC by 4.1% in the fourth quarter. Vontobel Asset Management now owns 1,915,494 shares of the medical technology company’s stock valued at $154,575,000 after buying an additional 74,733 shares during the last quarter. Finally, EQIS Capital Management boosted its stake in shares of Medtronic PLC by 651.1% in the fourth quarter. EQIS Capital Management now owns 15,292 shares of the medical technology company’s stock valued at $1,176,000 after buying an additional 13,256 shares during the last quarter.

Shares of Medtronic PLC (NYSE:MDT) opened at 75.59 on Wednesday. Medtronic PLC has a one year low of $55.54 and a one year high of $79.50. The stock has a market cap of $106.29 billion and a price-to-earnings ratio of 43.19. The company has a 50 day moving average of $76.21 and a 200-day moving average of $74.57.

Medtronic PLC (NYSE:MDT) last issued its quarterly earnings results on Thursday, December 3rd. The medical technology company reported $1.03 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.00 by $0.03. The company had revenue of $7.10 million for the quarter. During the same period in the previous year, the company posted $0.96 earnings per share. Medtronic PLC’s revenue for the quarter was up 61.7% on a year-over-year basis. On average, analysts anticipate that Medtronic PLC will post $4.38 earnings per share for the current year.

The business also recently declared a quarterly dividend, which was paid on Friday, January 15th. Investors of record on Thursday, December 24th were issued a dividend of $0.38 per share. This is an increase from Medtronic PLC’s previous quarterly dividend of $0.26. This represents a $1.52 annualized dividend and a dividend yield of 2.01%. The ex-dividend date of this dividend was Tuesday, December 22nd.

Several equities analysts recently issued reports on the stock. Deutsche Bank reiterated a “buy” rating on shares of Medtronic PLC in a research note on Thursday, October 15th. RBC Capital reiterated an “outperform” rating on shares of Medtronic PLC in a research note on Tuesday, September 29th. BTIG Research reiterated a “buy” rating and issued a $84.00 target price on shares of Medtronic PLC in a research note on Wednesday, October 21st. Evercore ISI upgraded shares of Medtronic PLC from a “hold” rating to a “buy” rating and boosted their target price for the company from $70.94 to $80.00 in a research note on Thursday, October 8th. Finally, Zacks Investment Research upgraded shares of Medtronic PLC from a “hold” rating to a “buy” rating and set a $84.00 target price for the company in a research note on Saturday, January 16th. Four analysts have rated the stock with a hold rating, fifteen have issued a buy rating and two have given a strong buy rating to the stock. Medtronic PLC has a consensus rating of “Buy” and an average target price of $86.13.

In related news, VP Richard Kuntz sold 13,715 shares of the stock in a transaction on Friday, December 4th. The stock was sold at an average price of $78.06, for a total transaction of $1,070,592.90. Following the completion of the sale, the vice president now directly owns 108,086 shares of the company’s stock, valued at $8,437,193.16. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Bryan C. Hanson sold 5,000 shares of the stock in a transaction on Friday, January 8th. The stock was sold at an average price of $75.00, for a total value of $375,000.00. Following the sale, the executive vice president now directly owns 106,514 shares of the company’s stock, valued at $7,988,550. The disclosure for this sale can be found here.

Medtronic plc (NYSE:MDT) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes Cardiac Rhythm & Heart Failure, Coronary & Structural Heart and Aortic & Peripheral Vascula. Its Minimally Invasive Technologies Group segment includes Surgical Solutions and Patient Monitoring and Recovery. Its Restorative Therapies Group segment includes Spine, Neuromodulation, Surgical Technologies and Neurovascular. Its Diabetes Group segment includes Intensive Insulin Management, Non-Intensive Diabetes Therapies and Diabetes Services & Solutions. Medtronic, Inc. is a subsidiary of the Company.

12 Month Chart for NYSE:MDT

Receive News & Ratings for Medtronic PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic PLC and related companies with MarketBeat.com's FREE daily email newsletter.